User:Da322

There have been no new classes of human antibiotics in over 30 years, resulting in deadly superbug outbreaks with no new medicines to stop it. Recce Pharmaceuticals Ltd (the Company) has developed a whole new class of synthetic antibiotics to tackle that threat.

The Company's lead candidate RECCE® 327 has been through several, rigorous safety and efficacy pre-clinical trials, up to the Food and Drug Administration (FDA) standards. The lead candidate has demonstrated confident activity against a broad range of extensively drug resistant (XDR) Gram-negative and Gram-positive bacterial infections, including their superbug forms.